Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of BC3402, a Novel Anti-TIM3 Agent, in Combination With Tremelimumab Plus Durvalumab (STRIDE) in Advanced, Unresectable Hepatocellular Carcinoma

Next Previous
Trial Profile

A Phase Ib/II Study of BC3402, a Novel Anti-TIM3 Agent, in Combination With Tremelimumab Plus Durvalumab (STRIDE) in Advanced, Unresectable Hepatocellular Carcinoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 23 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BC 3402 (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Feb 2026 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 29 Sep 2025 Planned initiation date changed from 1 Aug 2025 to 1 Nov 2025.
  • 24 Jun 2025 Planned initiation date changed from 1 Jun 2025 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top